Senl_H19x22P
/ SenlangBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 25, 2022
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
(clinicaltrials.gov)
- P=N/A; N=100; Recruiting; Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
CAR T-Cell Therapy • New trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22 • IFNG • IL10 • IL6 • TNFA
1 to 1
Of
1
Go to page
1